Evaluation of Gut Microbiome Diversity in Breast Cancer Survivors Following Active Cancer Therapy
Categories (click each to see list of all clinical trials associated with that category): Breast (ONC), Cancer Prevention and Control (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Tenner, Laura
Contact Information:
Susan Blumel, RN
402-559-9183
sblumel@unmc.edu
Summary
Aim 1: Establish a cohort of breast cancer survivors to evaluate the gut microbiota diversity within 1-12 months after completing active cancer therapy (Surgery, radiation, or chemotherapy).
Aim 2: Compare baseline gut microbiome diversity between breast cancer survivors who received chemotherapy treatment versus chemotherapy naïve survivors.
Aim 3: Compare baseline gut microbiome diversity between premenopausal and postmenopausal breast cancer survivors, specifically identifying the presence or absence of bacteria known to play a role in estrogen metabolism in the gut microbiota.